Multiple sclerosis (MS) is a highly heterogeneous disease with regard to presenting symptoms, disease activity, relapse, and rate of disability progression. Although there is no cure for MS, a plethora of diverse current and emerging disease-modifying therapies aim to slow disease progression, reduce relapses, and limit disability. However, clinical uncertainties create questions regarding the diagnosis, treatment, and overall management of patients with MS. These questions include: How do we recognize symptoms and accurately diagnose MS? Which therapies should be used? When is the best time to initiate, switch, and/or discontinue treatment? How do we incorporate continuously emerging real-world data into treatment decision-making? How do we optimally manage symptoms while minimizing treatment side effects and improve a patient's health-related quality of life? How do we facilitate shared decision-making and patient-centered care?

This interactive live symposium series will bring together MS experts to present and discuss the latest criteria and methodologies involved in MS diagnosis, to evaluate the most recent clinical trial and real-world data on MS treatment strategies, and to optimize patient-centered management to improve outcomes for patients with MS. This program will include breakout sessions to discuss case studies from the perspectives of the neurologist, the MS specialty nurse, and the primary care provider.

The goal of this program is to provide neurologists, primary care physicians, nurse practitioners, physician assistants, nurses and other healthcare providers who treat patients with MS with the latest science and clinical issues related to the management of patients with MS as well as the opportunity to discuss cases with local MS experts.

This activity is intended for neurologists, primary care physicians, nurse practitioners, physician assistants, nurses, other healthcare providers who treat patients with MS, as well as patients and their caregivers. No prerequisites required.

After attending this activity, the participant will demonstrate the ability to:

• ASSESS the most recent clinical and real word data on approved MS DMTs.
• EVALUATE the most recent evidence-based data and potential clinical implications of new and emerging DMTS for relapsing and progressive MS.
• RECOGNIZE the role of patient preferences, disease-specific factors, and shared decision-making in informing MS treatment and management.
• APPLY up-to-date clinical knowledge to develop both practice-specific and interprofessional strategies to individualized MS management plans.

The Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The Johns Hopkins School of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This 4.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity.